Attovia Therapeutics poised to surge in Nasdaq debut after upsized $289 million IPO

Attovia Therapeutics

05/08/2026 15:53

** Attovia Therapeutics ATTO.O on track to open well above offer price in Nasdaq debut after upsized $289 million U.S. IPO 
** Stock recently indicated to open at $24 apiece vs $17 IPO price
** San Carlos, California-based ATTO late Tuesday sold 17 million shares in an upsized IPO at $17 apiece
** ATTO, which is developing treatments for immune-mediated diseases, had initially marketed about 12.5 million shares priced between $15 and $17 apiece
** Its lead programs include ATTO-1310, which is being developed to treat chronic pruritic diseases
** Morgan Stanley, Leerink Partners, Citigroup and RBC Capital Markets acted as joint book-running managers for offering

 (Reporting by Arasu Kannagi Basil in Bengaluru)
 ((ArasuKannagi.Basil@thomsonreuters.com;))